The Visibility Gap
Every dashboard has a blind spot. My work is making it visible before it shows up in EBITDA.
By the time the problem appears in EBITDA, the organization may have been signaling trouble for months. Quiet meetings, rising turnover, fragile workflows, and temporary performance lifts are not diagnoses, but they are reasons to investigate.
The Visibility Gap is the distance between what leadership believes is happening, what people inside the practices actually experience, and what the financials eventually reveal.
Finding the cause early can mean the difference between a manageable correction, another expensive recovery effort, or something far worse: another practice closing its doors.
Not a QoE. Not a consultant.
- 01
A quality-of-earnings review verifies the numbers. I verify the explanation behind them.
- 02
Consultants are paid to sell the fix. I don’t implement, so my only job is getting the diagnosis right.
- 03
Management chooses what you see. I choose what to examine.
The lines of inquiry
What AOX Ops investigates
- 01
Follow the money
Same-store growth, location-level contribution, refunds, financing fallout, cash conversion, and what prior operating investments achieved.
- 02
Follow the patient
The actual journey from inquiry through consultation, clinically appropriate treatment, financing, and collected revenue, including where handoffs fail.
- 03
Follow the behavior
Turnover, incentives, employee workarounds, silence in feedback channels, key-person dependence, and what happens when extraordinary management intervention ends.
- 04
Follow the decision
What leadership believed, what it approved, how the initiative was implemented, whether it worked, and whether improvement lasted.
From early signals to decision-grade evidence
My instinct tells me where to look. The evidence determines what I conclude.
Three versions of the same business
- 1
The investment narrative
What investors are told: the forecast, the growth thesis, executive explanations, budget requests, and the measures leadership uses to define success.
- 2
The operating reality
What the business does: inquiry handling, appointment access, show rates, clinical capacity, case acceptance, collections, labor deployment, location-level economics, and follow-through.
- 3
The decision architecture
Why outcomes persist: who makes decisions, which assumptions are challenged, what incentives reward, where accountability ends, and who has the authority to correct the root cause.
THE VISIBILITY GAP | INDEPENDENT INVESTOR DIAGNOSTIC
IllustrativeA $12M EBITDA business. Five practices hold much of the investment thesis together.
Would you approve the next capital request without testing why those five outperform?
Founder-led analysis of financial concentration, operating-model repeatability, firsthand on-site evidence, and executive capital decisions.
SIMULATED ORGANIZATION / NOT AN ACTUAL CLIENT ENGAGEMENT. All amounts, people and decisions are fictional; no former-employer or patient records are used.
A profitable platform can still carry concentrated risk.
Illustrative 50-location dental organization; annual EBITDA in millions of dollars.
Top 5 locations
78.6%of net location-level EBITDA
of positive location-level EBITDA
- Net location-level EBITDA
- $14.0M
- Corporate overhead
- ($2.0M)
- Consolidated EBITDA
- $12.0M
Square areas are proportional to annual EBITDA. The other 45 locations net $3.0M: $5.0M from the next 15 locations plus ($2.0M) from the bottom 30 locations. 78.6% is $11.0M of $14.0M net location-level EBITDA; 68.75% is $11.0M of $16.0M positive location-level EBITDA.
Location-level to consolidated
- Top 5 locations
- $11.0M
- Next 15 locations
- $5.0M
- Bottom 30 locations
- ($2.0M)
- Net location-level EBITDA
- $14.0M
- Corporate overhead
- ($2.0M)
- Consolidated EBITDA
- $12.0M
What this actually means
The five strongest locations generate 68.75% of positive location-level EBITDA ($11M of $16M) and 78.6% of net location-level EBITDA ($11M of $14M). Neither measure describes revenue share or collected cash.
What happens when the top five slow down?
A simplified sensitivity analysis; not a forecast.
Stress test
- Top-five EBITDA baseline
- $11.0M
- Assumed decline
- 20%
- Illustrative lost EBITDA
- $2.2M
- Revised consolidated EBITDA
- $9.8M
- Company-wide EBITDA reduction
- 18.3%
Calculation: $11.0M x 20% = $2.2M; $12.0M - $2.2M = $9.8M. This assumes no offsetting changes in other locations, overhead, pricing or costs.
What I would test
I would request 24 months of monthly location P&Ls; and collections, provider tenure and productivity, referral sources, marketing by site, local market conditions, surgery capacity and the reconciliation between practice earnings and central overhead.
Outperformance may reflect execution, market demand, clinician reputation or several factors together. I would compare matched practices before assigning a cause.
Treatment sold is not money collected.
Illustrative monthly funnel for a subset of locations. All counts are fictional.
- 1,000Leads generated
- 400Consultations booked40% of leads
- 100Consultations attended25% of booked
- 40Treatment accepted40% of attended
- 30Cases funded75% of accepted
- Cases completed and collectedRequires transaction-level reconciliation
Where the investigation goes
I would reconcile the original lead source through human contact, appointment outcome, clinical consultation, financing, surgery and the actual banked receipt. Accepted treatment, patient deposits, production and net collections must remain separate measures.
Before funding another solution, test the last one.
Hypothetical decision: management commissions a $400,000 annual external sales-consulting engagement after missing revenue targets.
- Original investment thesis
- What did management expect the consulting to fix?
- Operating baseline
- Show rate, conversion, funding, collections and margin
- Evidence of change
- Comparable locations and trends before and after
- Decision ownership
- Who approved the spend and defined stopping rules?
- Financial result
- Verified incremental contribution profit
Break-even financial test
- Annual consulting expense
- $400,000
- Incremental contribution margin
- 40%
- Required incremental net collections
- $1.0M
At a hypothetical 40% incremental contribution margin, the consulting expense needs $1.0M of genuinely incremental net collections to break even ($400,000 / 0.40). At a 25% margin, it requires $1.6M. This simplified illustration excludes other incremental costs and timing effects.
The question is not whether external sales consulting is inherently effective or wasteful. It is whether leadership diagnosed the right constraint, tested alternatives and measured the actual return.
What would justify the next capital decision?
An illustrative committee recommendation, conditional on proper access to authorized records.
- 1Reconcile earningsValidate location-level EBITDA and corporate adjustments.
- 2Test repeatabilityCompare strongest practices with matched markets and providers.
- 3Trace patient economicsConnect lead quality and conversion to net receipts.
- 4Reconstruct major decisionsMeasure spending against the original hypothesis and results.
- 5Stage new capitalUse small pilots, measurable milestones and stopping rules.
Illustrative recommendation
Do not approve broad discretionary expansion spending solely because consolidated performance appears strong. Authorize targeted diligence first. Stronger reconciled data, repeatable mature-site results and demonstrated initiative returns could support further investment; unexplained losses or unsupported forecasts could warrant revised underwriting or governance protections.
I go into the practices to test the story.
On-site observation and structured interviews, with appropriate access and confidentiality protections.
What I personally do
I visit selected locations, observe operating workflows, and interview the people responsible for delivering results: executives, regional leaders, clinicians, practice managers, Smile Consultants and front-office teams. I compare what is described in board reporting with what I can substantiate inside the practices.
Fieldwork to financial evidence
| Observe | Evidence |
|---|---|
| Observe lead intake and scheduling | Reconcile callback logs, response times, and show rates. |
| Observe consultations and follow-up | Compare conversion and funded-case records to workflow. |
| Interview frontline and regional teams | Test stated policies against actual practices and decision rights. |
| Interview executives | Reconstruct assumptions, approvals, response to failures. |
| Triangulate observed gaps | Match findings to collections, margin, capacity and costs. |
How I handle evidence
Observations and interview accounts are not conclusions by themselves. I corroborate them against authorized source records, document limitations, and distinguish systematic problems from isolated examples. Interviews are appropriately authorized; patient privacy, workplace obligations and confidential information are protected.
PUBLIC METHODOLOGY SAMPLE. All figures are hypothetical. Not a valuation, quality-of-earnings opinion, assurance opinion, or recommendation to acquire or sell a security.